What question did this study set out to answer?

February 19, 2026Clinical Cancer Research

Abstract PS4-08-29: Neoadjuvant antibody-drug conjugates for early-stage breast cancer: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

GSG. B. Silva ASA. R. Simões RSR. H. da Silva

Discussion

Member takes

Overview

A systematic review evaluates the efficacy of neoadjuvant antibody-drug conjugates in early-stage breast cancer, indicating high pathologic complete response rates, especially in HER2-positive cases.

Key Points

Evaluate the efficacy and safety of neoadjuvant antibody-drug conjugates in early-stage breast cancer regarding pathologic complete response rates.
Systematic search of PubMed, Embase, and Cochrane for studies on early-stage breast cancer using neoadjuvant ADCs.
Inclusion of phase I/II trials evaluating various ADCs and their payloads.
Exclusion criteria included adjuvant therapy studies and those lacking data for ADC treatment groups.
Meta-analyses performed using random-effects models to assess heterogeneity.
A total of 2,809 studies screened, with 23 meeting inclusion criteria.
1,762 patients analyzed, showing a pooled pathologic complete response rate of 36.94%.
HER2-positive subtype demonstrated the highest pCR rate of 52.51%, followed by triple-negative at 29.5%.
Adverse events reported included nausea, diarrhea, and alopecia, with manageable grade ≥3 events.

Cite This Study

Silva et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eee28 https://doi.org/10.1158/1557-3265.sabcs25-ps4-08-29

View Full Paper

Ask AI

Bookmark

February 19, 2026Clinical Cancer Research

Abstract PS4-08-29: Neoadjuvant antibody-drug conjugates for early-stage breast cancer: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

GSG. B. Silva ASA. R. Simões RSR. H. da Silva

Discussion

Member takes

Overview

A systematic review evaluates the efficacy of neoadjuvant antibody-drug conjugates in early-stage breast cancer, indicating high pathologic complete response rates, especially in HER2-positive cases.

Key Points

Evaluate the efficacy and safety of neoadjuvant antibody-drug conjugates in early-stage breast cancer regarding pathologic complete response rates.
Systematic search of PubMed, Embase, and Cochrane for studies on early-stage breast cancer using neoadjuvant ADCs.
Inclusion of phase I/II trials evaluating various ADCs and their payloads.
Exclusion criteria included adjuvant therapy studies and those lacking data for ADC treatment groups.
Meta-analyses performed using random-effects models to assess heterogeneity.
A total of 2,809 studies screened, with 23 meeting inclusion criteria.
1,762 patients analyzed, showing a pooled pathologic complete response rate of 36.94%.
HER2-positive subtype demonstrated the highest pCR rate of 52.51%, followed by triple-negative at 29.5%.
Adverse events reported included nausea, diarrhea, and alopecia, with manageable grade ≥3 events.

Cite This Study

Silva et al. (2026) studied this question.

synapsesocial.com/papers/6996a84cecb39a600b3eee28 https://doi.org/10.1158/1557-3265.sabcs25-ps4-08-29

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark